Sodium Valproate: Health Services
Commons · Question 106960 · Tabled 20 Jan 2026 · Department of Health and Social Care · Official record
Answered 29 Jan 2026
Question
Asked by Bob Blackman
To ask the Secretary of State for Health and Social Care, what steps are being taken to ensure cumulative drug toxicity and polypharmacy risks are actively monitored in people prescribed sodium valproate.
Answer
Answered by Zubir Ahmed, 29 Jan 2026
There are established systems within the National Health Service to ensure that cumulative drug toxicity and polypharmacy risks are actively monitored in people prescribed sodium valproate. In practice, this involves establishing arrangements for assessin...